preclinics logotype

Funding and Cooperations

Funding

Since 8/2018: Establish of a nephelometry based method for testing oligoclonal and polyclonal antibody-antigen binding.
Brief description of the project
preclinics provides pharmacological tests in the preclinical phase on behalf of biotechnological and pharmaceutical companies and medical device manufacturers. Another important area is the immunization of various species for the production of antibodies for therapeutic and diagnostic purposes on behalf of various customers. Currently, rabbits, sheep, goats and new world camels (llamas, alpacas) are regularly immunised at preclinics. While some customers produce monoclonal antibodies from the animals' B-cells, preclinics itself can so far only offer polyclonal antibodies from these animals or RNA/cDNA from new world camels. However, since not all customers are proficient in the methodology for producing monoclonal rabbit antibodies, preclinics cannot offer these customers an adequate service and therefore cannot realise these projects.
It is therefore important for preclinics to expand its existing expertise in the field of contract immunisation in order to be able to act as a general provider for all types of requests in the market.
This programme for Brandenburger Innovationsfachkräfte (BIF) " Employment of a working student within the company innovation project" was financed as a project by the European Social Fund (ESF) via the Brandenburg Ministry of Employment, Social Affairs, Health, Women and Institutions (MASGF).

Since 2/2019 Installing a company own animal welfare management system.
This project was also funded by the European Social Fund (ESF) and the Federal State of Brandenburg via the Ministry for Labour, Social Affairs, Health, Women and Facility (MASGF).

Our research project in cooperation with Fraunhofer Institute for Cell Therapy and Immunology (IZI), sponsored by EFRE:
Since 4/2019 Development and production of VHH fusion antibodies for diagnostic and therapeutic use.

Since 4/2019 Creation of a technology platform for the diagnosis and therapy of mrsa
In this project, an improved method for the production and selection of camellia antibody fragments will be established. Based on a selected antigen (MRSA) an innovative technology platform for the diagnosis and therapy of antigens will be developed, which will serve as proof of concept for the transfer of the new technology to other fields of application. At the same time, the "VHH immunojunction" concept developed in preclinics will be applied, further developed and validated for various selected targets.
In the overall context of the project, preclinics will focus on the development and research of VHH antibodies with functional immunojunctions and the demonstration of their functionality and effectiveness in vivo and in vitro. All novel production methods and binding molecules resulting from the development of the process can be considered as products that will find their way into medical diagnostics or therapy. Various marketing channels are conceivable, such as out-licensing the method, offering services or selling end products. The aim of the ProFIT project is to map the entire VHH value chain through targeted research and development work and the establishment of production including marketing.
NEW: In the course of the SARS-CoV-2 pandemic, our project was expanded to include this pathogen. Experience already gained will now be used to advance the therapeutic application of specific immunojunctions against the causative agent of Covid-19.
This project is funded by the European Regional Development Fund and the Federal State of Brandenburg.

Cooperations:

Dept. Chemical Life Sciences, University of Parma, ITALY www.unipr.it
Stiftungsprofessur Immuntechnologie, University of Potsdam, GERMANY
Medizinische Hochschule Hannover, GERMANY

For more information see:
www.esf.brandenburg.de or www.ec.europa.eu

esf
lb_soziales
eufond
eu_sozialfonds_rechtsbuendig-unter-der-fahne.3879046